Differences In HTA Acceptance Rates Across Disease Areas: A Comparison Between Four HTA Agencies

被引：0
|
作者：
Vadlamudi, N. K. [1 ]
Griffiths, E. A. [2 ]
机构：
[1] Parexel Int, Hyderabad, Andhra Pradesh, India
[2] PAREXEL, London, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.766
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP174
引用
收藏
页码：A287 / A287
页数：1
相关论文
共 50 条
  • [21] DIFFERENCES IN EVIDENCE REQUIREMENTS IN ONCOLOGY DRUG ASSESSMENT BETWEEN HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES AND EMA AND HTA BODIES AMONG THEMSELVES
    Wolters, S.
    Jansen, C.
    Postma, M. J.
    [J]. VALUE IN HEALTH, 2020, 23 : S465 - S466
  • [22] IS THE INSTITUTE OF CLINICAL AND ECONOMIC REVIEW (ICER) SET UP FOR SUCCESS? A COMPARISON BETWEEN ICER AND EX-US HTA AGENCIES
    Skolas, K.
    Pruefert, A.
    Yee, S.
    van Engen, A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A476 - A476
  • [23] COMPARISON OF HEALTH TECHNOLOGY ASSESSMENTS AND TIME TO REIMBURSEMENT FOR ORPHAN DRUGS FROM FOUR HTA AGENCIES: OPPORTUNITIES AND CHALLENGES IN FRANCE, GERMANY, ENGLAND AND SCOTLAND
    Stefani, I
    Poon, C.
    Raj, N.
    Kelly, S.
    [J]. VALUE IN HEALTH, 2020, 23 : S757 - S757
  • [24] AN EVALUATION OF SPECIAL CONSIDERATIONS IN THE ASSESSMENT AND DECISION-MAKING PROCESSES ACROSS HTA AGENCIES FOR DRUGS FOR RARE DISEASES
    Harricharan, S.
    Musat, M.
    Wiltshire, L.
    Hubscher, E.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S5 - S5
  • [25] WHAT DO HTAS LOOK LIKE AROUND THE WORLD? A COMPARISON OF SOUTH KOREAN AND BRITISH HTA AGENCIES
    Versoza, L.
    Adler, B.
    Blumenthal, J.
    Chang, R.
    Ho, Y.
    Rubinstein, E. R.
    Rubinstein, J. L.
    Sliman, R. C.
    Smith, M. Z.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A814 - A814
  • [26] COMPARISON OF FACTORS INFLUENCING RECENT REIMBURSEMENT DECISIONS OF ADVANCED NON-SMALL-CELL LUNG CANCER THERAPIES ACROSS LEADING HTA AGENCIES
    Kumar, P.
    Jyothsna, B. S.
    Outteridge, G.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A135 - A135
  • [27] COST-EFFECTIVENESS REVIEWS BY HTA AGENCIES: A COMPARISON OF FACTORS LEADING TO UNFAVOURABLE REVIEWS FOR ONCOLOGY AGENTS
    Smith, N.
    Beckerman, R.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A7 - A7
  • [28] HTA decision-making for drugs for rare diseases: comparison of processes across countries
    Tania Stafinski
    Judith Glennie
    Andrea Young
    Devidas Menon
    [J]. Orphanet Journal of Rare Diseases, 17
  • [29] DIFFERENCES IN HTA COVERAGE RECOMMENDATIONS: COMPARING OPHTHALMOLOGY DRUG REIMBURSEMENT DECISIONS IN FOUR EUROPEAN COUNTRIES
    Tramonti, G.
    Smith, L.
    Bennison, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S430 - S431
  • [30] HTA decision-making for drugs for rare diseases: comparison of processes across countries
    Stafinski, Tania
    Glennie, Judith
    Young, Andrea
    Menon, Devidas
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2022, 17 (01)
12345